Document Reference: Document Issue Number: Document Issue Date: Page 1 of 2 ME-STA-015 01 07/01/2021



GN92 Chemotherapy Statement

Product Brand:	Nitrex Ultra Sensitive	
Product Description:	Powder free nitrile examination glove - blue	
Product Code:	GN92	

The Nitrex Ultra Sensitive nitrile examination grade gloves were submitted by the OEM factory, to Akron Rubber Development Laboratory Inc, for testing in accordance with ASTM D 6978-05: Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs (test report reference: PN 122150B).

ASTM D 6978-05 was the preferred standard against which the gloves were tested; as opposed to EN 374-1 owing to:

- EN 374-1 does not take into account chemotherapy drugs.
- Testing is conducted at a temperature similar to that of the hand $(35 \pm 2^{\circ}C)$ as opposed to the EN 374-1 test temperature of $23 \pm 1^{\circ}C$.
- The ASTM breakthrough occurs at one hundredth less concentration than that of EN 374-1. The ASTM breakthrough occurs when the permeation rate reaches 0.01 μg/cm²/min against that of EN 374-1 which occurs at 1 μg/cm²/min.

Minimum breakthrough time:

Test Chemotherapy Drug & Concentration	Minimum measured breakthrough detection time (Specimen 1,2,3) (minutes)	Steady state permeation rate (Specimen 1,2,3) (µg/cm²/minute)	Other Observations
Carmustine (BCNU) 3.3 mg/ml (3,300 ppm)	10.1 (10.2,10.1,10.2)	N/A*	Moderate swelling and no degradation
Cisplatin 1.0 mg/ml (1,000 ppm)	No breakthrough up to 240	N/A	Slight swelling and no degradation
Cyclophosphamide (Cytoxan) 20 mg/ml (20,000 ppm)	No breakthrough up to 240	N/A	Slight swelling and no degradation
Cytarabine 100 mg/ml (100,000 ppm)	No breakthrough up to 240	N/A	Slight swelling and no degradation
Dacarbazine (DTIC) 10.0 mg/ml (10,000 ppm)	No breakthrough up to 240	N/A	Slight swelling and no degradation
Doxorubicin Hydrochloride 2.0 mg/ml (2,000 ppm)	No breakthrough up to 240	N/A	Slight swelling and no degradation
Etoposide (Toposar) 20.0 mg/ml (20,000 ppm)	No breakthrough up to 240	N/A	Slight swelling and no degradation
Fluorouracil 50.0 mg/ml (50,000 ppm)	No breakthrough up to 240	N/A	Slight swelling and no degradation
Ifosfamide 50.0 mg/ml (50,000 ppm)	No breakthrough up to 240	N/A	Slight swelling and no degradation
Methotrexate 25 mg/ml (25,000 ppm)	No breakthrough up to 240	N/A	Slight swelling and no degradation
Mitomycin C 0.5 mg/ml (500 ppm)	No breakthrough up to 240	N/A	Slight swelling and no degradation

T: +44 (0) 1708 863868 E: enquiries@medicareproducts.com W. www.medicareproducts.com

Document Reference: Document Issue Number: Document Issue Date: Page 2 of 2 ME-STA-015 01 07/01/2021



Mitoxantrone, 2.0 mg/ml (2,000 ppm)	No breakthrough up to 240	N/A	Slight swelling and no degradation
Paclitaxel (Taxol) 6.0 mg/ml (6,000 ppm)	No breakthrough up to 240	N/A	Moderate swelling and no degradation
Thiotepa 10.0 mg/ml (10,000 ppm)	30.2 (40.4,40.4,30.2)	1.5 (1.4,1.6,1.6)	Slight swelling and no degradation
Vincristine Sulfate 1.0 mg/ml (1,000 ppm)	No breakthrough up to 240	N/A	Slight swelling and no degradation

Note: *The steady state was not available at the end of the testing period due to the strong permeation process (absorbance values out of linear range).

